Embla Medical (EMBLA) Q3 2024 earnings summary

Executive summary

• Achieved 7% organic sales growth and 11% local currency growth in Q3 2024, with strong EMEA performance in prosthetics, neuro products, and patient care; Americas remained soft.

• EBITDA margin improved to 22%, up three percentage points year-over-year, reflecting cost reductions and better product mix.

• Net profit rose 58% to $22 million (10% of sales), up from $14 million (7% of sales) in Q3 2023.

• Integration of Fior & Gentz progressing, expanding neuro orthotics into new markets.

• U.S. Medicare expanded coverage for bionic knees to K2 patients, expected to gradually increase addressable market.

Financial highlights

• Gross profit margin rose to 63% in Q3 2024, up from 62% year-over-year, driven by cost reduction and product mix.

• EBITDA margin reached 22%, a three percentage point increase from Q3 last year.

• Net profit grew 58% to $22 million (10% of sales), up from $14 million (7% of sales) in Q3 2023.

• CapEx was $9 million (4% of sales), with facility expansions largely completed; CapEx expected to normalize at 3-4% of sales.

• Strong free cash flow supported by operational cash generation, working capital, and lower CapEx.

Outlook and guidance

• Reiterated full-year guidance of 6-8% organic sales growth and around 20% EBITDA margin before special items.

• No meaningful 2024 impact expected from new product launches or U.S. Medicare reform; full launch of Nāvī and ICON bionic knees set for early 2025.

• R&D costs expected to be slightly higher in Q4 on a run-rate basis, but no significant step-up as a percentage of sales.

• CapEx expected to normalize at 3-4% of sales; effective tax rate guided at 24%.

• Special items for 2024 expected at $4 million, mainly related to the FIOR & GENTZ acquisition and cost reduction initiatives.